Research Papers:

Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies

Nikita Pozdeyev _, Minjae Yoo, Ryan Mackie, Rebecca E. Schweppe, Aik Choon Tan and Bryan R. Haugen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:51619-51625. https://doi.org/10.18632/oncotarget.10010

Metrics: PDF 3184 views  |   HTML 4678 views  |   ?  


Nikita Pozdeyev1, Minjae Yoo1, Ryan Mackie1, Rebecca E. Schweppe1, Aik Choon Tan1,*, Bryan R. Haugen1,*

1Department of Medicine, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA

*Two senior authors contributed equally to this work

Correspondence to:

Nikita Pozdeyev, email: [email protected]

Keywords: database integration, drug sensitivity, pharmacogenomics, cancer, cell line

Received: April 08, 2016    Accepted: May 29, 2016    Published: June 14, 2016


The consistency of in vitro drug sensitivity data is of key importance for cancer pharmacogenomics. Previous attempts to correlate drug sensitivities from the large pharmacogenomics databases, such as the Cancer Cell Line Encyclopedia (CCLE) and the Genomics of Drug Sensitivity in Cancer (GDSC), have produced discordant results. We developed a new drug sensitivity metric, the area under the dose response curve adjusted for the range of tested drug concentrations, which allows integration of heterogeneous drug sensitivity data from the CCLE, the GDSC, and the Cancer Therapeutics Response Portal (CTRP). We show that there is moderate to good agreement of drug sensitivity data for many targeted therapies, particularly kinase inhibitors. The results of this largest cancer cell line drug sensitivity data analysis to date are accessible through the online portal, which serves as a platform for high power pharmacogenomics analysis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10010